ACP Trainees Conference
Click here to download the programme. To download the presentations, click the titles.
Friday 11 October
||Welcome drinks reception
||Welcome dinner (with an after-dinner speech from Dr Marcia Hall Followed by music entertainment)
Saturday 12 October
With thanks to our sponsors *:
* None of whom have had an input into the meeting agenda or content.
Click here to view the delegate list. The password was included in your Know Before You Go email.
Click here to download the speakers' biographies.
Appointed as a Consultant Medical Oncologist in 2003 in Portsmouth , specialising in Breast, Upper GI and Neuroendocrine Tumours.
Have always been an active supporter of ACP, and was a founder member of the Organising Committee for the New Consultants Meeting, which continues successfully. Currently ACP Wessex regional representative.
Dr Alison May Berner is a medical oncology trainee and clinical research fellow, currently undertaking a PhD in colorectal cancer genomics. After developing an interest in inequalities in cancer care for transgender patients, she commenced a part-time registrar post at the Gender Identity Clinic London, part of the Tavistock and Portman NHS Trust, and is now a fully qualified specialist in adult gender identity medicine. As well as assessing patients for gender affirming treatments, she acts as an advice and liaison service for transgender patients with cancer. She is running a number of research, quality improvement and education projects at the interface of oncology and gender identity with partners including the CRUK, Prostate Cancer UK, Jo’s Cervical Cancer Trust, RCR and ACP.
Educated at Cheltenham Ladies College (St Austins 1975-81). Trained in medicine at Guy’s Hospital Medical School - q1986. Completed PhD at the Imperial Cancer Research Fund (now CRUK) working on cyclins and kinases.
Currently I work at Mount Vernon Cancer Centre, Hillingdon Hospital and Wexham Park Hospital. I have a chair in translational oncology at Brunel University where I am exploring the use of circulating tumour cells and cell free DNA in the management of cancer patients. I am also attempting to interest my clinical MVCC colleagues in academic pursuits to foster the ongoing research opportunities local to Mount Vernon Cancer Centre.
I predominantly treat gynaecological cancers but also some colorectal cancers. I am PI of many clinical trials at MVCC in both gynaecological and colorectal cancers and Chief Investigator for CoRInTH (pembrolizumab with chemoradiation in locally advanced T3-4 anal cancers) and CeNTuRIOn (rucaparib versus rucaparib nivolumab versus rucaparib, nivolumab and ipilimumab in relapsed ovarian cancer) clinical trials. I was also CI for the OSCAR and METRO-BIBF clinical trials which are reporting this year. I am a member of the National Cancer Research Institute (NCRI) Ovarian Cancer subgroup –participant on the Guideline Development Group for Ovarian Cancer convened under the umbrella of NICE. My professional aims are to care effectively for my patients with cancer, using evidence -based medicine where available and offering research trials of drugs and/or techniques where appropriate and possible. I am currently Lead Clinician for Research and Development at Mount Vernon Cancer Centre.
Daniel is a specialist trainee based at UCL currently undertaking a PhD at King's College London in imaging of immunotherapy, earlier detection of toxicity and understanding the clinical implications of intra-tumoural heterogeneity. Having completed an MSc in Medical Education, Daniel has a keen interest in this field leading on several research projects and setting up and leading Regional Teaching in London. He is also contributing to redevelopment of the Medical Oncology Curriculum as trainee representative on the Specialty Advisory Committee and Medical Oncology / Clinical Oncology Curriculum Working Group. He is an active member of the Association of Cancer Physicians Trainee Committee and London representative for NOTCH. Daniel is also interested in better understanding the unique healthcare needs of LGBTQ+ patients with cancer and is pleased to be collaborating with Alison Berner, as a leader and advocate in this field.
I trained in Cambridge and Manchester and after house jobs, medical SHO rotations and a flirtation with histopathology, completed an MD in mechanisms of endocrine resistance in breast cancer with Prof Mitch Dowsett at the Royal Marsden Hospital. I then completed my Medical Oncology specialty training in North London.
I have been a Breast Oncology Consultant at the Royal Free Hospital since 2002. During that time, I have developed a major interest in post-graduate specialty training and taken on a number of local, regional and national educational roles, most recently taking over as Chair of the Medical Oncology Specialty Advisory Committee of the JRCPTB in 2017.
Dr Olsson-Brown trained in Medicine at the University of Liverpool having first completed a BSc (Hons) in Pharmacology. She is a Medical Research Council (MRC) Clinical Research Fellow based at the University of Liverpool and a practicing Medical Oncology Registrar at the Clatterbridge Cancer Centre. Her clinical interest is in melanoma with clinical and research foci in the mechanisms and management of irAEs across all tumour groups. She has established the regional immune-oncology service and contributed to a number of national guidelines. She is the Deputy Chair of the Immuno-Oncology Committee. Her PhD is based on understanding the immunological events that occur in the presence of immunotherapy that lead to toxicity and the mechanisms thereof. She has particular interests in colitis, thyroiditis and skin toxicity. She is also Chair of the Royal college of Physicians of Edinburgh Trainees and Members committee, Vice-Chair of the UK National Oncology Trainees Collaborative for Healthcare Research and a trainee representative of the Medical Oncology speciality advisory committee.
Mark has been an ACP trainee for the last 4 years. Based in the midlands (leicester) whilst doing his PhD on the translational use of circulating tumour DNA, he is an imperial trainee currently doing an OOPE in oncogenetics at the Royal Marsden.
Dr Naureen Starling is a Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of gastrointestinal (GI) cancers and an Honorary Clinical Senior Lecturer within the Division of Clinical Studies at the Institute of Cancer Research.
Her research interests in GI cancers (oesophageal, gastric, pancreatic, neuroendocrine and colorectal) are focussed on earlier phase clinical trials, novel therapeutics and the delivery of individualised medicine to patients with gastrointestinal cancers. She is the Associate Director of Clinical Research and Clinical Lead for the Royal Marsden’s West Wing Clinical Research Centre. She is the Upper GI Lead for the South London Cancer Research Network, and serves on the UK National Cancer Research Institute oesophago-gastric sub-group.
Dr Starling also holds educational roles including the NIHR Training Lead for the RM/Institute of Cancer Research Biomedical Research Centre, member of the ICR/Imperial College CRUK Major centre training committee, Deputy Training Program Director (one of three) for South London Medical Oncology Training, member of the pan-London specialist Medical oncology training committee and member of the Medical Oncology National Recruitment steering committee.
Professor Fiona Thistlethwaite is a Medical Oncology Consultant and Immune-Oncology lead for ECMT (Experimental Cancer Medicines Team) at The Christie NHS Foundation Trust and Honorary Professor at The University of Manchester. She graduated from The University of Cambridge MB PhD programme in 1999. Her PhD, under the supervision of Professor Sir Martin Evans, explored the molecular mechanisms that lead to cancer in inherited breast cancer syndromes. She became a consultant at The Christie in 2007 and joined ECMT in 2016. Fiona has been actively involved in clinical trial development for many years with a research focus on early phase clinical trials in immune-oncology, particularly adoptive cell therapies, combination immunotherapies and immune biomarkers. She is the Programme Director for the iMATCH (Innovate Manchester Advanced Therapy Centre Hub) consortium which was awarded £7M to establish one of three Innovate funded ATTC (Advanced Therapy Treatment Centres) in the UK. In addition, she is Co-Chair of Manchester Immuno-Oncology Network, Co-Lead of the Cancer Immunology Branch of the Lydia Becker Institute and a member of the ESMO Congress Scientific Committee (Immunotherapy Track).
Ivor Williams is a designer, developing new ways of thinking about and experiencing death, dying and loss in the 21st century. He leads the end-of-life care projects at the Helix Centre, an innovation design lab inside the Institute of Global Health Innovation led by Lord Ara Darzi at St Mary’s Hospital in London. He co-founded the Helix Centre’s first spin-out venture, Digital Care Planning, with the mission to bring critical illness and end of planning to the mainstream. As director of the tech-for-good company Humane Engineering, he co-leads the development of Cove, a flagship mental health app available on the NHS, and quoted as “one of the best mental health apps” by the Guardian newspaper. In 2018, he was named a New Radical by innovation foundation Nesta for “pioneering a human-centric approach to the experience of dying, bereavement and grief”.